Physician profile
Daniel Deblasio
NPI 1669467551
$358.34
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $121 · 2022: $13.21 · 2023: $35.25 · 2024: $34.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verastem, INC. | $46.69 | 2019 | |
| Genentech USA, INC. | $46.33 | 2019-2024 | Alecensa, Phesgo, Tecentriq |
| Bayer Healthcare Pharmaceuticals INC. | $40.88 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $37.87 | 2019-2022 | |
| Siemens Medical Solutions USA, INC. | $35.25 | 2023 | Edge |
| Pharmacyclics LLC, An Abbvie Company | $34.48 | 2019-2020 | |
| Genzyme Corporation | $23.11 | 2019 | |
| Merck Sharp & Dohme LLC | $20.54 | 2024 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $16.54 | 2019 | |
| Celgene Corporation | $16.18 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.18 | 2020 | |
| Amgen INC. | $13.98 | 2020 | |
| Boston Scientific Corporation | $12.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Deblasio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.